11 completed, 8 terminated, 7 unknown, 4 recruiting. 20 Phase 2, 12 Phase 3, 6 Phase 1, 1 Phase 4.
Follow CHOP: new trials by email Literature Review of CHOP trials Research Report on CHOP
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| New Genotype-guided Treatment in Newly Diagnosed PTCL Azacitidine plus Selinexor with CHOP, Decitabine plus Selinexor with CHOP, Zeprumetostat plus chidamide with CHOP - Peripheral T-cell Lymphoma (PTCL) | Phase 1 / Phase 2 | Not yet recruiting | Ruijin Hospital | 108 | 2026-07-01 | 2026-07-16 |
| Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A Obinutuzumab, CHOP, Bendamustine - Follicular Lymphoma Grade 3A | Phase 2 | Not yet recruiting | Sun Yat-sen University | 133 | 2025-05-01 | 2025-05-08 |
| A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma Linperlisib - Peripheral T Cell Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Shanghai YingLi Pharmaceutical Co. Ltd. | 606 | 2024-09-10 | 2024-08-12 |
| Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma Etoposide, Cytarabine, PEG-rhG-CSF - Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization | Phase 3 | Recruiting | The Affiliated People's Hospital of Ningbo University | 99 | 2024-08-01 | 2025-12-04 |
| To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL Belinostat Injection, Pralatrexate Injection, CHOP - Peripheral T Cell Lymphoma | Phase 3 | Active not recruiting | Acrotech Biopharma Inc. | 504 | 2023-10-04 | 2026-10-15 |
| Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma Mosunetuzumab (SC), Rituximab (R), Bendamustine - Marginal Zone Lymphoma | Phase 3 | Recruiting | The Lymphoma Academic Research Organisation | 260 | 2023-09-05 | 2026-06-15 |
| Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL Parsaclisib, CHOP - PI3Kδ Inhibitor, Parsaclisib | Phase 1 / Phase 2 | Unknown | Fudan University | 30 | 2022-03-01 | 2022-02-14 |
| Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) Zandelisib, Rituximab, Bendamustine - Follicular Lymphoma (FL), Non Hodgkin Lymphoma | Phase 3 | Terminated | MEI Pharma, Inc. | 82 | 2021-08-13 | 2024-11-04 |
| PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients Vincristine Sulfate Liposome, CHOP, R-CHOP - Hematologic Diseases | Phase 1 | Unknown | Acrotech Biopharma Inc. | 56 | 2020-08-15 | 2020-04-16 |
| Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma CHOP, CHOP+X - Peripheral T-cell Lymphoma | Phase 2 | Unknown | Ruijin Hospital | 96 | 2020-07-29 | 2023-06-13 |
| Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma DA-EPOCH, Rituximab, CHOP - Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 132 | 2019-08-05 | 2026-10-26 |
| Treatment of Newly Diagnosed Peripheral T-cell Lymphoma Apatinib, CHOP Regimen - Newly Diagnosed Peripheral T-cell Lymphoma | Phase 4 | Unknown | Zhengzhou University | 100 | 2018-09-01 | 2018-08-15 |
| PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy CHOP, CHOP Plus Lanzoprazole, CHOP Plus Famotidine - Lymphoma | Phase 3 | Recruiting | Sherief Abd-Elsalam | 60 | 2018-08-01 | 2018-08-27 |
| Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients Obinutuzumab, Ibrutinib, CHOP - Richter Syndrome | Phase 2 | Terminated | Northwell Health | 3 | 2017-06-19 | 2023-06-01 |
| Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients. Obinutuzumab, Ibrutinib, CHOP - Lymphoma, B-Cell | Phase 2 | Terminated | Fondazione Italiana Linfomi - ETS | 1 | 2016-09-01 | 2017-03-20 |
| Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO) Duvelisib, Rituximab, R-CHOP - Lymphoma | Phase 2 | Withdrawn | SecuraBio | 2015-12-01 | 2021-03-17 | |
| Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL HLX01, Rituximab, CHOP - B-cell Non Hodgkin's Lymphoma | Phase 3 | Completed | Shanghai Henlius Biotech | 407 | 2015-10-01 | 2022-05-09 |
| Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL CHOP, fractionated ICED - Peripheral T-cell Lymphoma | Phase 2 | Unknown | Samsung Medical Center | 134 | 2015-09-23 | 2020-10-22 |
| Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) Belinostat, CHOP - Peripheral T-cell Lymphoma | Phase 1 | Completed | Acrotech Biopharma Inc. | 23 | 2013-05-01 | 2020-01-03 |
| Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma Romidepsin + CHOP, CHOP - Peripheral T-cell Lymphoma | Phase 3 | Completed | The Lymphoma Academic Research Organisation | 421 | 2013-01-01 | 2023-01-10 |
Showing 20 of 36. Sign in to see all of them.
Lymphoma, T-Cell, Peripheral (9) · Lymphoma, Non-Hodgkin (7) · Lymphoma, B-Cell (6) · Lymphoma (4) · Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Cardiotoxicity (1) · Hematologic Diseases (1) · Hematologic Neoplasms (1) · Leukemia (1) · Lymphoma, AIDS-Related (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, T-Cell (1)
Acrotech Biopharma Inc. (3) · Fudan University (2) · Hoffmann-La Roche (2) · Ruijin Hospital (2) · Sun Yat-sen University (2) · The Lymphoma Academic Research Organisation (2) · Alaunos Therapeutics (1) · Charite University, Berlin, Germany (1) · Eisai Inc. (1) · Emergent BioSolutions (1) · Fondazione Italiana Linfomi - ETS (1) · French National Agency for Research on AIDS and Viral Hepatitis (1) · GlaxoSmithKline (1) · Heidelberg University (1) · International Extranodal Lymphoma Study Group (IELSG) (1)
United States (12) · China (9) · France (7) · Italy (7) · Germany (6) · South Korea (5) · Spain (5) · Belgium (4) · Canada (4) · Poland (4) · Portugal (4) · Australia (3) · Greece (3) · Hungary (3) · Taiwan (3)
Andreas Sarris, MD (1) · Anthony D. Ho, Ph.D., Prof. (1) · Christopher J Melani, M.D. (1) · Dominique Costagliola (1) · Emanuele Zucca, MD (1) · Ephraim P Hochberg, MD (1) · Francois Boue, MD (1) · Guan ZhongZhen (1) · Hagop Youssoufian, MD (1) · Jacqueline Barrientos, MD (1)
PMID 19525191, PMID 22173060, PMID 23278639, PMID 24895339, PMID 27992268, PMID 28935843, PMID 30770362, PMID 32299513, PMID 33394214, PMID 33602316, PMID 34843406, PMID 38364196, PMID 39175480, PMID 40802906, PMID 42699559
2015 (2)